Free Trial
→ Nvidia’s record quarter could send this new type of AI soaring (From Brownstone Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$41.66
-2.6%		$46.62
$27.00
▼
$55.67
$6.99B0.322.15 million shs1.01 million shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$32.11
-3.4%		$39.03
$15.95
▼
$45.42
$6.63B0.841.51 million shs1.18 million shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$90.95
-1.6%		$105.15
$74.50
▼
$122.20
$6.23B2.01756,726 shs705,363 shs
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$26.94
-3.2%		$31.18
$13.50
▼
$44.60
$1.76B-0.9821,068 shs236,347 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
+2.42%+6.50%-7.25%-22.56%+37.67%
Immunovant, Inc. stock logo
IMVT
Immunovant
-1.10%-0.72%-15.29%-17.06%+96.75%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-0.41%-6.20%-10.02%-19.23%-6.64%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-1.66%+1.02%-15.36%+0.54%+27.90%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$41.66
-2.6%		$46.62
$27.00
▼
$55.67
$6.99B0.322.15 million shs1.01 million shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$32.11
-3.4%		$39.03
$15.95
▼
$45.42
$6.63B0.841.51 million shs1.18 million shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$90.95
-1.6%		$105.15
$74.50
▼
$122.20
$6.23B2.01756,726 shs705,363 shs
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$26.94
-3.2%		$31.18
$13.50
▼
$44.60
$1.76B-0.9821,068 shs236,347 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
+2.42%+6.50%-7.25%-22.56%+37.67%
Immunovant, Inc. stock logo
IMVT
Immunovant
-1.10%-0.72%-15.29%-17.06%+96.75%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-0.41%-6.20%-10.02%-19.23%-6.64%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-1.66%+1.02%-15.36%+0.54%+27.90%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alkermes plc stock logo
ALKS
Alkermes
2.74
Moderate Buy$54.4730.75% Upside
Immunovant, Inc. stock logo
IMVT
Immunovant
2.58
Moderate Buy$44.0037.04% Upside
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
2.76
Moderate Buy$140.6754.67% Upside
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
2.56
Moderate Buy$46.7173.41% Upside

Current Analyst Ratings Breakdown

Latest ZBIO, IMVT, RYTM, and ALKS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/2/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/30/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$41.00 ➝ $48.00
9/30/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$55.00
9/30/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$45.00
9/30/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$44.00
9/24/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/24/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingPositive
9/24/2026
Alkermes plc stock logo
ALKS
Alkermes
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$50.00
9/24/2026
Alkermes plc stock logo
ALKS
Alkermes
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold$50.00
9/23/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/22/2026
Alkermes plc stock logo
ALKS
Alkermes
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$56.00
(Data available from 10/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alkermes plc stock logo
ALKS
Alkermes
$1.48B4.74$1.67 per share24.93$11.02 per share3.78
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/A$4.19 per shareN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$239.92M25.98N/AN/A$2.08 per share43.73
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$1M1,755.80N/AN/A$4.51 per share5.97
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alkermes plc stock logo
ALKS
Alkermes
$241.66M$0.38109.63173.58N/A3.96%4.15%2.19%10/28/2026 (Estimated)
Immunovant, Inc. stock logo
IMVT
Immunovant
-$505.61M-$2.82N/AN/AN/AN/A-69.59%-62.49%11/9/2026 (Estimated)
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$196.54M-$3.11N/AN/AN/A-85.59%-159.87%-44.00%11/3/2026 (Estimated)
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$377.74M-$8.99N/AN/AN/AN/A-122.45%-58.04%11/12/2026 (Estimated)

Latest ZBIO, IMVT, RYTM, and ALKS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/3/2026Q3 2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.7234N/AN/AN/A$84.84 millionN/A
10/28/2026Q3 2026
Alkermes plc stock logo
ALKS
Alkermes
-$0.0781N/AN/AN/A$463.47 millionN/A
8/12/2026Q2 2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$1.12-$1.77-$0.65-$1.77$15.00 million$1.00 million
8/6/2026Q1 2027
Immunovant, Inc. stock logo
IMVT
Immunovant
-$0.6289-$0.75-$0.1211-$0.75$7.10 million$7.10 million
8/4/2026Q2 2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.8072-$0.73+$0.0772-$0.73$67.66 million$71.26 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alkermes plc stock logo
ALKS
Alkermes
N/AN/AN/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/AN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/AN/AN/AN/AN/A
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$0.050.18%N/AN/A N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alkermes plc stock logo
ALKS
Alkermes
0.82
2.30
1.85
Immunovant, Inc. stock logo
IMVT
Immunovant
N/A
7.27
7.27
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
3.45
3.20
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
1.57
9.93
9.93

Institutional Ownership

CompanyInstitutional Ownership
Alkermes plc stock logo
ALKS
Alkermes
95.21%
Immunovant, Inc. stock logo
IMVT
Immunovant
47.08%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A

Insider Ownership

CompanyInsider Ownership
Alkermes plc stock logo
ALKS
Alkermes
4.59%
Immunovant, Inc. stock logo
IMVT
Immunovant
1.90%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
5.90%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
22.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alkermes plc stock logo
ALKS
Alkermes
2,050167.76 million160.06 millionOptionable
Immunovant, Inc. stock logo
IMVT
Immunovant
315206.55 million202.63 millionOptionable
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
41468.53 million64.49 millionOptionable
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
16765.18 million50.84 millionN/A

Recent News About These Companies

Zenas BioPharma to Host Virtual R&D Event on October 27, 2026
October 6 at 7:31 AM  |  quiverquant.comQ
Zenas BioPharma to Host Virtual R&D Event
October 6 at 7:05 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375333/0/en/zenas-biopharma-to-host-virtual-r-d-event.html
Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve
October 5 at 6:00 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4951917-zenas-biopharma-obexelimab-is-being-graded-on-the-wrong-curve-maintain-buy
Zenas BioPharma (NASDAQ:ZBIO) Earns "Outperform" Rating from Wedbush
October 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31077012
HC Wainwright Reaffirms "Buy" Rating for Zenas BioPharma (NASDAQ:ZBIO)
October 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31076698
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Up 7.1% - Still a Buy?
October 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-zenas-biopharma-nasdaq-zbio-stock-price-up-71-still-a-buy-2026-10-01/
Zenas BioPharma (NASDAQ:ZBIO) Stock Falls 4.5% - Should You Sell?
October 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31073980
Zenas BioPharma's Obexelimab Faces Larger IgG4-RD Opportunity, Wedbush Says
September 30, 2026  |  marketscreener.comM
Wedbush Reaffirms Outperform Rating for Zenas BioPharma (NASDAQ:ZBIO)
September 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-wedbush-reaffirms-outperform-rating-for-zenas-biopharma-nasdaq-zbio-2026-09-30/
Zenas BioPharma (NASDAQ:ZBIO) Earns Buy Rating from HC Wainwright
September 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-zenas-biopharma-nasdaq-zbio-earns-buy-rating-from-hc-wainwright-2026-09-30/
Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript
September 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4950694-zenas-biopharma-inc-zbio-discusses-obexelimab-prelaunch-strategy-and-commercial-opportunity
Transcript : Zenas BioPharma, Inc. - Special Call
September 29, 2026  |  marketscreener.comM
Zenas BioPharma (NASDAQ:ZBIO) Shares Down 4.5% - Here's What Happened
September 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-zenas-biopharma-nasdaq-zbio-shares-down-45-heres-what-happened-2026-09-29/
Zenas BioPharma (NASDAQ:ZBIO) Trading Down 8.2% - Here's Why
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-zenas-biopharma-nasdaq-zbio-trading-down-82-heres-why-2026-09-23/
Why Is Zenas BioPharma (ZBIO) Filing More Than $240 Million In Shelves?
September 23, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/why-zenas-biopharma-zbio-filing-043226725.html
Can Zenas BioPharma’s (ZBIO) Clinical Pipeline Justify Its Heavy Cash Burn?
September 23, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/news/can-zenas-biopharmas-zbio-clinical-pipeline-justify-its-heavy-cash-burn-1842776/
Bank of America Corp DE Acquires New Holdings in Zenas BioPharma, Inc. $ZBIO
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-acquires-new-holdings-in-zenas-biopharma-inc-zbio-2026-09-23/
Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR ...
September 22, 2026  |  marketscreener.comM
Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026
September 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/22/3366153/0/en/zenas-biopharma-announces-upcoming-presentations-of-obexelimab-data-in-igg4-related-disease-at-the-igg4ward-6th-international-symposium-on-igg4-related-disease-and-acr-convergence-.html
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 18, 2026
September 21, 2026  |  biospace.comB
Zenas BioPharma Grants Stock Options and RSUs to Newly Hired Employees as Inducement Awards
September 18, 2026  |  quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alkermes stock logo

Alkermes NASDAQ:ALKS

$41.66 -1.10 (-2.57%)
Closing price 03:59 PM Eastern
Extended Trading
$41.65 -0.01 (-0.02%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Immunovant stock logo

Immunovant NASDAQ:IMVT

$32.11 -1.14 (-3.43%)
Closing price 03:59 PM Eastern
Extended Trading
$32.12 +0.01 (+0.02%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Rhythm Pharmaceuticals stock logo

Rhythm Pharmaceuticals NASDAQ:RYTM

$90.95 -1.50 (-1.62%)
Closing price 03:59 PM Eastern
Extended Trading
$90.84 -0.11 (-0.13%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Zenas BioPharma stock logo

Zenas BioPharma NASDAQ:ZBIO

$26.94 -0.89 (-3.20%)
Closing price 03:59 PM Eastern
Extended Trading
$26.96 +0.02 (+0.08%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas